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Olfaction, 1 of the 5 principal human senses, serves a variety of critical health‐related roles ranging from the ability to detect health hazards such as fire or toxic fumes, to psychosocial implications such as the ability to enjoy food. Its importance is underscored by the well‐established association of olfactory dysfunction (OD) with multiple comorbidities, including depression, impaired cognition, and decreased nutrition.[^1^](#alr22624-bib-0001){ref-type="ref"}, [^2^](#alr22624-bib-0002){ref-type="ref"} Furthermore, OD is associated with a negative impact on quality of life, increased social isolation, and mortality in a "dose‐dependent" fashion.[^1^](#alr22624-bib-0001){ref-type="ref"}, [^3^](#alr22624-bib-0003){ref-type="ref"}

Despite the importance and implications of OD, it is often overlooked by scientific and medical communities. Approximately 5% of the general population is believed to be affected by functional anosmia secondary to a variety of etiologies, including infectious, trauma, chronic rhinosinusitis (CRS), iatrogenic, and idiopathic causes.[^4^](#alr22624-bib-0004){ref-type="ref"} Of these etiologies, post‐infectious OD is one of the most prevalent.[^4^](#alr22624-bib-0004){ref-type="ref"}, [^5^](#alr22624-bib-0005){ref-type="ref"} Though post‐infectious OD may be secondary to bacteria, fungi, or other rare organisms, viruses are the most common etiology.[^4^](#alr22624-bib-0004){ref-type="ref"}, [^6^](#alr22624-bib-0006){ref-type="ref"} Examples of causative viruses include human rhinovirus, coronavirus, parainfluenza, and Epstein‐Barr viruses.[^7^](#alr22624-bib-0007){ref-type="ref"} Notably, the novel coronavirus severe acute respiratory syndrome (SARS)‐CoV‐2, responsible for the COVID‐19 pandemic, has been associated with at least temporary olfactory loss in a large proportion of affected patients from recently reported cohorts.[^8^](#alr22624-bib-0008){ref-type="ref"}, [^9^](#alr22624-bib-0009){ref-type="ref"}, [^10^](#alr22624-bib-0010){ref-type="ref"} This pandemic has renewed interest in post‐viral olfactory dysfunction (PVOD) and evidence‐based treatments. At this time, the natural history of PVOD cannot be clearly anticipated. While some patients will experience transient dysosmia or parosmia, followed by return of olfactory function, many patients experience permanent OD.[^4^](#alr22624-bib-0004){ref-type="ref"}, [^11^](#alr22624-bib-0011){ref-type="ref"} The efficacy and evidence for treatment options are also lacking. Though corticosteroids are commonly used, there are a plethora of other potential therapies available, as well as evidence that suggests a role for olfactory training.[^12^](#alr22624-bib-0012){ref-type="ref"} Study size, quality of evidence, and efficacy of these options are wide‐ranging.

This review sought to provide a comprehensive review of the supporting evidence for the treatment of PVOD, with accompanying, evidence‐based recommendations when possible. Though recommendations are provided, this review is not meant to replace clinical judgment, but rather arm clinicians with an improved understanding of the available treatment strategies for PVOD in an effort to optimize patient outcomes and identify areas of further inquiry for this common condition.

Materials and methods {#alr22624-sec-0060}
=====================

Study design {#alr22624-sec-0070}
------------

Recommendations from The Clinical Practice Guideline Manual,[^13^](#alr22624-bib-0013){ref-type="ref"} Conference on Guideline Standardization (COGS) instrument,[^14^](#alr22624-bib-0014){ref-type="ref"} and the iterative process described by Rudmik and Smith[^15^](#alr22624-bib-0015){ref-type="ref"} were used to create this evidence‐based review with recommendations. According to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines,[^16^](#alr22624-bib-0016){ref-type="ref"} a systematic review of the literature was performed, guided by the PICOS (populations, interventions, comparisons, outcomes, and study design) described in Table [1](#alr22624-tbl-0001){ref-type="table"}.

###### 

Search strategy---PICOS (population, intervention, comparator, outcomes, study design) approach

+:-------------+:--------:+:-----------------------------------------------------------------------------+
| Population   | Included | Patients with post‐viral olfactory dysfunction                               |
+--------------+----------+------------------------------------------------------------------------------+
|              | Excluded | Alternate etiologies of olfactory dysfunction                                |
+--------------+----------+------------------------------------------------------------------------------+
| Intervention | Included | Medical therapy                                                              |
|              |          |                                                                              |
|              |          | Surgical intervention                                                        |
|              |          |                                                                              |
|              |          | Olfactory training                                                           |
|              |          |                                                                              |
|              |          | Acupuncture                                                                  |
+--------------+----------+------------------------------------------------------------------------------+
| Comparator   | Included | Patients with post‐viral olfactory dysfunction who did not undergo treatment |
+--------------+----------+------------------------------------------------------------------------------+
| Outcomes     | Included | Subjective olfactory measurements                                            |
|              |          |                                                                              |
|              |          | Objective olfactory scores                                                   |
+--------------+----------+------------------------------------------------------------------------------+
| Studies      | Included | ≥5 subjects                                                                  |
|              |          |                                                                              |
|              |          | Intervention for olfactory dysfunction                                       |
+--------------+----------+------------------------------------------------------------------------------+
|              | Excluded | Non‐English                                                                  |
|              |          |                                                                              |
|              |          | Pre‐existing or alternate etiology of olfactory dysfunction                  |
|              |          |                                                                              |
|              |          | Natural history cohorts                                                      |
+--------------+----------+------------------------------------------------------------------------------+
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Literature search strategy {#alr22624-sec-0080}
--------------------------

A systematic search was conducted on March 26, 2020 using MEDLINE via PubMed, Embase, Cochrane Library, Web of Science, Scopus, and Google Scholar. The first 44 citations were extracted from Google Scholar. All other databases were searched from inception to search date. A focused literature search was performed using a combination of the following keywords: "post‐viral olfactory dysfunction," "anosmia," "dysosmia," "parosmia," "olfaction disorders," "olfactory impairment," "olfactory disturbance," "olfactory loss," "smell disorder," "viral infection," "virus," "viral disease," "common cold," and "respiratory tract infection." Additional records were identified by examining the references of articles obtained for review. Records were obtained by a qualified medical library informationist (S.M.S.).

Inclusion and exclusion criteria {#alr22624-sec-0090}
--------------------------------

Studies investigating the effects of medical, surgical, or olfactory training interventions on olfaction in patients with PVOD were included. Abstracts containing subjects with PVOD in addition to other etiologies of OD were included. Only studies with ≥5 subjects were included. Exclusion criteria included non‐English language and patient populations composed exclusively of those with OD secondary to etiologies other than PVOD (eg, idiopathic, trauma, and CRS). Studies without a defined intervention were excluded. Additionally, case reports, letters to the editor, abstracts, and book chapters were not included.

Data extraction, collection, and risk of bias assessment {#alr22624-sec-0100}
--------------------------------------------------------

Studies were managed in Covidence (Veritas Health Innovation Ltd, Melbourne, Australia) and duplicates were removed. Articles were independently reviewed by 3 authors (D.X.X., N.H., C.P.O.). Following abstract review, the remaining studies underwent a full text review. Outcome data were independently extracted from studies meeting inclusion criteria and disagreements were resolved by consensus. Studies were graded by quality in accordance with the 2011 Oxford Center for Evidence‐Based Medicine Criteria (Table [2](#alr22624-tbl-0002){ref-type="table"}).[^17^](#alr22624-bib-0017){ref-type="ref"}

###### 

Quality rating according to Oxford Center for Evidence‐Based Medicine[^17^](#alr22624-bib-0017){ref-type="ref"}

  --- ------------------------------------------------------------------------------------------------
  1   Properly powered and conducted randomized clinical trial; systematic review with meta‐analysis
  2   Well‐designed controlled trial without randomization; prospective comparative cohort trial
  3   Case‐control studies; retrospective cohort study
  4   Case series with or without intervention; cross‐sectional study
  5   Opinion of respected authorities; case reports
  --- ------------------------------------------------------------------------------------------------
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Risk of bias was assessed for each included study. Level 1 and 2 evidence studies were evaluated with the Modified Cochrane Collaboration Tool for Assess Risk of Bias (Table [3](#alr22624-tbl-0003){ref-type="table"}).[^18^](#alr22624-bib-0018){ref-type="ref"} The Newcastle‐Ottawa Quality Assessment Scale was utilized for level 3 and 4 evidence studies (Table [4](#alr22624-tbl-0004){ref-type="table"}).[^19^](#alr22624-bib-0019){ref-type="ref"}

###### 

Modified Cochrane Collaboration Tool for assessing risk of bias in level 1 and 2 evidence studies[^18^](#alr22624-bib-0018){ref-type="ref"}

  Study (year)                                                              Sequence generation   Allocation concealment   Blinding of participants and personnel   Blinding of outcome assessors   Incomplete outcome data   Selective outcome reporting   Other sources of bias
  ------------------------------------------------------------------------ --------------------- ------------------------ ---------------------------------------- ------------------------------- ------------------------- ----------------------------- -----------------------
  Nguyen and Patel[^54^](#alr22624-bib-0054){ref-type="ref"} (2018)               Unclear                Unclear                            High                                High                          Low                         Low                        Low
  Philpott et al.[^32^](#alr22624-bib-0032){ref-type="ref"} (2017)                  Low                    Low                              Low                                  Low                          Low                         Low                        Low
  Konstantinidis et al.[^52^](#alr22624-bib-0052){ref-type="ref"} (2016)           High                  Unclear                            High                                 Low                          Low                         Low                        Low
  Whitcroft et al.[^33^](#alr22624-bib-0033){ref-type="ref"} (2016)               Unclear                  Low                              Low                                 High                          Low                         Low                        Low
  Altundag et al.[^51^](#alr22624-bib-0051){ref-type="ref"} (2015)                  Low                  Unclear                            High                                High                          Low                         Low                        Low
  Damm et al.[^49^](#alr22624-bib-0049){ref-type="ref"} (2014)                      Low                    Low                              High                                 Low                          Low                         Low                        Low
  Reden et al.[^44^](#alr22624-bib-0044){ref-type="ref"} (2012)                   Unclear                Unclear                            Low                                  Low                          Low                         Low                        Low
  Reden et al.[^36^](#alr22624-bib-0036){ref-type="ref"} (2011)                   Unclear                Unclear                            Low                                 High                          Low                         Low                        Low
  Blomqvist et al.[^29^](#alr22624-bib-0029){ref-type="ref"} (2003)                 Low                    Low                              Low                                  Low                          Low                         Low                        Low
  Quint et al.[^42^](#alr22624-bib-0042){ref-type="ref"} (2002)                   Unclear                Unclear                            High                                 Low                          Low                         Low                        Low
  Henkin et al.[^40^](#alr22624-bib-0040){ref-type="ref"} (1976)                    Low                    Low                              Low                                  Low                          Low                         Low                        Low
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###### 

Newcastle‐Ottawa Assessment Scale[^a^](#alr22624-tbl4-note-0001){ref-type="fn"} evaluating quality of level 3 and level 4 evidence studies[^19^](#alr22624-bib-0019){ref-type="ref"}

  Study (year)                                                              Selection grade (maximum 4 asterisks)   Comparability grade (maximum 2 asterisks)   Exposure grade (maximum 3 asterisks)         Total
  ------------------------------------------------------------------------ --------------------------------------- ------------------------------------------- -------------------------------------- --------------------
  Wang et al.[^37^](#alr22624-bib-0037){ref-type="ref"} (2018)                             \*\*\*                                       0                                       \*\*                       \*\*\*\*\*
  Kim et al.[^22^](#alr22624-bib-0022){ref-type="ref"} (2017)                               \*\*                                       N/A                                     \*\*\*                      \*\*\*\*\*
  Poletti et al.[^53^](#alr22624-bib-0053){ref-type="ref"} (2017)                         \*\*\*\*                                    \*\*                                     \*\*\*                  \*\*\*\*\*\*\*\*\*
  Whitcroft et al.[^34^](#alr22624-bib-0034){ref-type="ref"} (2017)                       \*\*\*\*                                    \*\*                                      \*\*                    \*\*\*\*\*\*\*\*
  Dai et al.[^56^](#alr22624-bib-0056){ref-type="ref"} (2016)                             \*\*\*\*                                    \*\*                                     \*\*\*                  \*\*\*\*\*\*\*\*\*
  Henkin et al.[^39^](#alr22624-bib-0039){ref-type="ref"} (2017)                           \*\*\*                                       0                                      \*\*\*                     \*\*\*\*\*\*
  Schopf et al.[^35^](#alr22624-bib-0035){ref-type="ref"} (2015)                          \*\*\*\*                                      0                                        \*                        \*\*\*\*\*
  Geißler et al.[^50^](#alr22624-bib-0050){ref-type="ref"} (2014)                           \*\*                                       N/A                                     \*\*\*                      \*\*\*\*\*
  Kollndorfer et al.[^55^](#alr22624-bib-0055){ref-type="ref"} (2014)                       \*\*                                       N/A                                      \*\*                        \*\*\*\*
  Konstantinidis et al.[^48^](#alr22624-bib-0048){ref-type="ref"} (2013)                  \*\*\*\*                                     \*                                      \*\*\*                   \*\*\*\*\*\*\*\*
  Fleiner et al.[^47^](#alr22624-bib-0047){ref-type="ref"} (2012)                         \*\*\*\*                                    \*\*                                     \*\*\*                  \*\*\*\*\*\*\*\*\*
  Schriever et al.[^23^](#alr22624-bib-0023){ref-type="ref"} (2012)                         \*\*                                       N/A                                      \*\*                        \*\*\*\*
  Fleiner and Goktas[^31^](#alr22624-bib-0031){ref-type="ref"} (2011)                      \*\*\*                                      N/A                                     \*\*\*                     \*\*\*\*\*\*
  Vent et al.[^57^](#alr22624-bib-0057){ref-type="ref"} (2010)                             \*\*\*                                     \*\*                                      \*\*                     \*\*\*\*\*\*\*
  Henkin et al.[^38^](#alr22624-bib-0038){ref-type="ref"} (2009)                           \*\*\*                                      N/A                                     \*\*\*                     \*\*\*\*\*\*
  Hummel et al.[^46^](#alr22624-bib-0046){ref-type="ref"} (2009)                          \*\*\*\*                                    \*\*                                     \*\*\*                  \*\*\*\*\*\*\*\*\*
  Seo et al.[^21^](#alr22624-bib-0021){ref-type="ref"} (2009)                               \*\*                                       \*                                      \*\*\*                     \*\*\*\*\*\*
  Stenner et al.[^25^](#alr22624-bib-0025){ref-type="ref"} (2008)                          \*\*\*                                       0                                       \*\*                       \*\*\*\*\*
  Fukazawa et al.[^30^](#alr22624-bib-0030){ref-type="ref"} (2005)                           \*                                        N/A                                       \*                           \*\*
  Heilmann et al.[^24^](#alr22624-bib-0024){ref-type="ref"} (2004)                        \*\*\*\*                                      0                                       \*\*                      \*\*\*\*\*\*
  Hummel et al.[^45^](#alr22624-bib-0045){ref-type="ref"} (2002)                            \*\*                                       N/A                                     \*\*\*                      \*\*\*\*\*
  Aiba et al.[^41^](#alr22624-bib-0041){ref-type="ref"} (1998)                              \*\*                                       \*                                      \*\*\*                     \*\*\*\*\*\*
  Mori et al.[^28^](#alr22624-bib-0028){ref-type="ref"} (1998)                             \*\*\*                                     \*\*                                      \*\*                     \*\*\*\*\*\*\*
  Ikeda et al.[^26^](#alr22624-bib-0026){ref-type="ref"} (1995)                              \*                                        N/A                                     \*\*\*                       \*\*\*\*
  Duncan et al.[^43^](#alr22624-bib-0043){ref-type="ref"} (1962)                             \*                                        N/A                                       \*                           \*\*

Higher number of asterisks indicate higher quality study. Maximum score for case control study is 9 asterisks, and maximum score for case series is 4 asterisks. For assessment of case series articles, questions regarding control group are not applicable.
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Development of recommendations {#alr22624-sec-0110}
------------------------------

Following the completion of the systematic review and evaluation of research quality, a summary was produced including the aggregate grade of evidence (A to D) and recommendations based on the American Academy of Pediatrics Steering Committee on Quality Improvement and Managements guidelines (Table [5](#alr22624-tbl-0005){ref-type="table"}).[^20^](#alr22624-bib-0020){ref-type="ref"} An aggregate grade of evidence was not provided for any intervention investigated by only a single study.

###### 

Recommendations based on defined grades of evidence[^20^](#alr22624-bib-0020){ref-type="ref"}

  Grade   Research quality                                                                                                   Preponderance of benefit over harm      Balance of benefit and harm
  ------- ------------------------------------------------------------------------------------------------------------------ -------------------------------------- -----------------------------
  A       Well‐designed RCTs                                                                                                 Strong recommendation                             Option
  B       Randomized controlled trials with minor limitations; overwhelming consistent evidence from observational studies   Strong recommendation/recommendation              Option
  C       Observational studies (case control and cohort design)                                                             Recommendation                                    Option
  D       Expert opinion; case report; reasoning from first principles                                                       Option                                       No recommendation
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The Clinical Practice Guideline Development Manual and COGS) instrument recommendations were followed,[^13^](#alr22624-bib-0013){ref-type="ref"} and in accordance with a previously described iterative process, each subsequent author reviewed, critiqued, and refined the recommendations.[^15^](#alr22624-bib-0015){ref-type="ref"} Any disagreements amongst the authors were debated electronically until a consensus was achieved. The goal of the recommendations aimed to incorporate the quality of the research in addition to the balance of benefit and harm. Recommendations were provided when sufficient evidence for an intervention was available.

Results {#alr22624-sec-0120}
=======

Search characteristics {#alr22624-sec-0130}
----------------------

Initial literature search yielded 524 manuscripts with an additional 28 manuscripts identified through other sources (Fig. [1](#alr22624-fig-0001){ref-type="fig"}). Following removal of duplicates and abstract screening, 99 studies underwent full text review and were assessed for eligibility. Thirty‐six studies were included with a total of 4640 patients with OD, of which 2183 patients (47.0%) had a post‐viral etiology.

![PRISMA flow diagram. PRISMA = Preferred Reporting Items for Systematic Reviews and Metaanalyses.](ALR-9999-na-g001){#alr22624-fig-0001}

Of these 36 studies, 13 exclusively examined PVOD, whereas 23 studies considered OD of PVOD and other etiologies. In all studies, a patient was considered to have PVOD if they presented with olfactory loss following a viral infection. In many studies, further detail of how this diagnosis of PVOD was made was not offered; however, 15 studies specifically distinguished PVOD from "idiopathic" or "unknown" causes of OD and 2 studies excluded patients with diagnoses of "idiopathic" or "unknown" causes. Olfactory outcomes included 21 studies that utilized Sniffin' Sticks, 3 with the University of Pennsylvania Smell Identification Test (UPSIT), 3 with the Toyota & Takagi olfactometer (T&T), 2 with the Cross‐Cultural Smell Identification Test (CCSIT), 2 with the Connecticut Chemosensory Clinical Research Center (CCCRC) test, 4 with olfactory thresholds from multiple odors, 1 with butanol threshold testing (BTT), and 8 with subjective symptoms using a Visual Analog Scale (VAS) and/or additional subjective scales. In studies that utilized Sniffin' Sticks, a composite score, "TDI," was calculated from the odor threshold (T), discrimination (D), and identification (I) subtest scores. Several studies utilized 2 or more olfactory outcome modalities. Regarding the quality of studies, 7 studies were level 1, 4 were level 2, 8 were level 3, and 17 were level 4. Mean follow‐up duration was 7.6 months (range 20 minutes‐72 months). One study did not specify a follow‐up duration. Summaries of included patients are included in Tables [6](#alr22624-tbl-0006){ref-type="table"}, [7](#alr22624-tbl-0007){ref-type="table"}, [8](#alr22624-tbl-0008){ref-type="table"}, [9](#alr22624-tbl-0009){ref-type="table"}, [10](#alr22624-tbl-0010){ref-type="table"}.

###### 

Summary of systemic steroid studies

+-------------------------------------------------------------------+----------------------------------------------+-----+--------------------------------------+----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------+--------------+-------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Author (year)                                                     | Study design                                 | LOE | PVOD subjects (n)/Total subjects (n) | Primary comparison                                                                           | Treatment details                                                                                               | Follow‐up    | Olfactory outcome | Results                                                                                                                                                                                                                                                                                                                                                               |
+:==================================================================+:=============================================+:===:+:====================================:+:=============================================================================================+:================================================================================================================+:============:+:=================:+:======================================================================================================================================================================================================================================================================================================================================================================+
| Seo et al.[^21^](#alr22624-bib-0021){ref-type="ref"} (2009)       | Randomized, nonblinded, parallel group trial | 3   | 71/71                                | Oral prednisolone + mometasone sprayOral prednisolone + mometasone + Gingko biloba           | Prednisolone 30 mg daily with taperMometasone 2 puffs/nasal cavity twice dailyGingko biloba 80 mg 3 times daily | 4 weeks      | BTT, CCSIT        | Scores on BTT and CCSIT significantly improved after treatment in both groups (*p* \< 0.001)Similar rates of improvement between monotherapy versus combination therapy \[BTT score change 1.4 ± 2.2 vs. 2.2 ± 2.9, (*p* = 0.22); CCSIT score change: 0.9 ± 1.7 vs. 1.9 ± 2.7, (*p* = 0.11)\]                                                                         |
+-------------------------------------------------------------------+----------------------------------------------+-----+--------------------------------------+----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------+--------------+-------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Kim et al.[^22^](#alr22624-bib-0022){ref-type="ref"} (2017)       | Retrospective case series                    | 4   | 178/491                              | Oral prednisoloneMometasone sprayOral prednisolone + mometasone spray                        | Prednisolone 40 mg daily with taperMometasone 0.1 mg/nasal cavity daily                                         | 1 month      | CCCRC, CCSIT      | 59.6% of PVOD patients showed recovery with treatmentShorter duration of PVOD associated with better treatment outcomes (*p* = 0.001)In all patients, the percentage of treatment group with smell recovery was significantly greater in the prednisolone + mometasone (54.8%) and prednisol1 only groups (55.0%) than the mometas1 only group (28.2%) (*p* \< 0.001) |
+-------------------------------------------------------------------+----------------------------------------------+-----+--------------------------------------+----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------+--------------+-------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Schriever et al.[^23^](#alr22624-bib-0023){ref-type="ref"} (2012) | Retrospective case series                    | 4   | 27/425                               | Oral methylprednisolone (all)                                                                | Methylprednisolone 40 mg daily with taper                                                                       | 2 weeks      | Sniffin' Sticks   | PVOD patients exhibited statistically significant increase in TDI after treatment with systemic steroids (mean increase 4.47 ± 7.09 points, *p* = 0.003)                                                                                                                                                                                                              |
+-------------------------------------------------------------------+----------------------------------------------+-----+--------------------------------------+----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------+--------------+-------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Stenner et al.[^25^](#alr22624-bib-0025){ref-type="ref"} (2008)   | Retrospective case series                    | 4   | 31/89                                | Oral betamethasone + budesonide sprayOral betamethasone, + budesonide spray + neomycin spray | Betamethasone 3.0 mg daily with taperBudesonide spray 1.5 mg twice dailyNeomycin spray 7.5 mg twice daily       | 12 weeks     | Sniffin' Sticks   | Oral steroids significantly improved TDI for patients of all etiologies (PVOD patient results not individually reported)Topical antibiotics and steroids were more likely to lead to improvement if the patient did not improve on oral steroids for patients of all etiologies                                                                                       |
+-------------------------------------------------------------------+----------------------------------------------+-----+--------------------------------------+----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------+--------------+-------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Heilmann et al.[^24^](#alr22624-bib-0024){ref-type="ref"} (2004)  | Retrospective,                               | 4   | 22/92                                | Oral prednisoloneMometasone spray                                                            | Prednisolone 40 mg daily with taperMometasone 0.1 mg/nasal cavity daily                                         | 21‐330 days  | Sniffin' Sticks   | Olfactory function improved after oral prednisolone in PVOD group (*p* = 0.05)Response to systemic therapy not correlated with age, gender, or duration of disease                                                                                                                                                                                                    |
|                                                                   |                                              |     |                                      |                                                                                              |                                                                                                                 |              |                   |                                                                                                                                                                                                                                                                                                                                                                       |
|                                                                   | nonrandomized parallel group case series     |     |                                      |                                                                                              |                                                                                                                 |              |                   |                                                                                                                                                                                                                                                                                                                                                                       |
+-------------------------------------------------------------------+----------------------------------------------+-----+--------------------------------------+----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------+--------------+-------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Ikeda et al.[^26^](#alr22624-bib-0026){ref-type="ref"} (1995)     | Case series                                  | 4   | 9/21                                 | Oral prednisolone (all)                                                                      | Prednisolone 40‐60 mg daily with taper                                                                          | Up to 1 year | T&T               | No significant improvement in odor recognition and detection thresholds in PVOD patients                                                                                                                                                                                                                                                                              |
+-------------------------------------------------------------------+----------------------------------------------+-----+--------------------------------------+----------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------+--------------+-------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+

Data presented as mean ± standard deviation.

BTT = butanol threshold test; CCCRC = Connecticut Chemosensory Clinical Research Center test; CCSIT = Cross‐cultural Smell Identification Test; LOE = level of evidence; PVOD = post‐viral olfactory dysfunction; TDI = threshold, discrimination, and identification score; T&T = Toyota & Takagi olfactometer; URI = upper respiratory infection.
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Systemic steroids {#alr22624-sec-0140}
-----------------

Six studies were performed using systemic steroids. Duration of follow‐up, olfactory testing, and dosing of systemic steroids varied widely (Table [6](#alr22624-tbl-0006){ref-type="table"}). Overall, 4 studies showed mild benefit with systemic steroids,[^21^](#alr22624-bib-0021){ref-type="ref"}, [^22^](#alr22624-bib-0022){ref-type="ref"}, [^23^](#alr22624-bib-0023){ref-type="ref"}, [^24^](#alr22624-bib-0024){ref-type="ref"} while study design in others prevented definitive conclusions.[^25^](#alr22624-bib-0025){ref-type="ref"}, [^26^](#alr22624-bib-0026){ref-type="ref"} Notably, Schriever et al. showed a statistically significant increase in TDI score (from 14.39 to 18.86; *p* = 0.003) after 2 weeks of treatment with oral methylprednisolone 40 mg daily and taper, though there was no comparison group. Furthermore, the mean improvement in TDI scores failed to reach the minimal clinically important difference (MCID) of 5.5.[^27^](#alr22624-bib-0027){ref-type="ref"} Olfactory improvement secondary to combination therapy of oral prednisolone and mometasone spray with Gingko biloba was found to be similar to that after oral prednisolone and mometasone spray alone.[^21^](#alr22624-bib-0021){ref-type="ref"}

**Summary**: **Aggregate evidence**: C (Level 3: 1 study, Level 4: 5 studies)**Benefit**: Improved objective olfaction across multiple psychophysical tests**Harm**: Potential side effects relating to systemic corticosteroids**Cost**: Minimal medication cost**Benefit‐Harm assessment**: Balance of benefit and harm**Value judgments**: Provider must consider the risk of systemic corticosteroids in setting of patient medical comorbidities, notably in setting of heterogeneous studies with limited use of controls and unknown clinical significance.**Recommendation level**: Option**Intervention**: In absence of additional risk factors, can offer short course of systemic therapy after thoroughly considering potential outcomes and treatment‐associated risks.

Topical or local therapies {#alr22624-sec-0150}
--------------------------

### Topical or local steroids {#alr22624-sec-0160}

Four studies assessed the effect of topical or local corticosteroids, including fluticasone proprionate, beclomethasone spray, and dexamethasone or betamethasone injections (Table [7](#alr22624-tbl-0007){ref-type="table"}).[^28^](#alr22624-bib-0028){ref-type="ref"}, [^29^](#alr22624-bib-0029){ref-type="ref"}, [^30^](#alr22624-bib-0030){ref-type="ref"}, [^31^](#alr22624-bib-0031){ref-type="ref"} One study did not specify the steroids used for treatment.[^28^](#alr22624-bib-0028){ref-type="ref"} Blomqvist et al. conducted a randomized control trial (RCT) of 40 patients that included 23 patients (57.5%) with PVOD and 7 patients (17.5%) with idiopathic loss. All patients had experienced a 2‐step improvement in BTT scores following a 10‐day taper of oral prednisolone from 40 mg/day and 200 µg/day of fluticasone proprionate and were subsequently randomized into continued nasal steroids, placebo, or no further treatment for an additional 2 months. There was no difference in olfactory outcomes amongst the 3 treatment groups.[^29^](#alr22624-bib-0029){ref-type="ref"}

###### 

Summary of topical or local therapy studies

  Author (year)                                                         Study design                                                     LOE   PVOD subjects (n) /Total subjects (n)  Primary comparison                                                                                                                                                                                                                     Treatment details                                                                                                            Follow‐up       Olfactory outcome    Results
  --------------------------------------------------------------------- --------------------------------------------------------------- ----- --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ----------------- ---------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Corticosteroids**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Blomqvist et al.[^29^](#alr22624-bib-0029){ref-type="ref"} (2003)     Randomized, double‐blinded, placebo‐controlled clinical trial     1                    23/40                  All patients showed BTT improvement of at least 2 steps following a 10‐day course of oral prednisolone 40 mg daily with taper and fluticasone spray, prior to being randomized to: Fluticasone proprionate sprayPlaceboControl group   Fluticasone proprionate 200 µg daily                                                                                         6 months            CCCRC, VAS       No difference in olfaction amongst the 3 groups
  Fleiner and Goktas[^31^](#alr22624-bib-0031){ref-type="ref"} (2011)   Prospective case series                                           4                    8/18                   Beclomethasone spray directed to the olfactory cleft (all)                                                                                                                                                                             Beclomethasone spray 250 µg twice daily                                                                                       4 weeks         Sniffin' Sticks     2/8 PVOD patients had ≥6 point improvement in TDINo effect of etiology, age, duration of disorder, or gender on prognosis for all patients
  Fukazawa et al.[^30^](#alr22624-bib-0030){ref-type="ref"} (2005)      Prospective, noncontrolled case series                            4                   133/133                 Dexamethasone or Betamethasone (all)                                                                                                                                                                                                   Dexamethasone 5 mg or Betamethasone 5 mg injections into olfactory cleft every 2 weeks for 16‐20 weeks                      16‐20 weeks           T&T, VAS        49.6% of PVOD patients demonstrated improvement on T&T olfactometry after treatment
  Mori et al.[^28^](#alr22624-bib-0028){ref-type="ref"} (1998)          Retrospective case series                                         4                   244/889                 Topical corticosteroids (not otherwise specified, all)                                                                                                                                                                                 Not otherwise specified                                                                                                   2 weeks‐2 years    T&T, Alinamin test   Olfaction improved in 58% of PVOD patients after treatmentIn PVOD patients, no correlation between gender, age, or duration of olfactory loss with prognosis
  **Sodium citrate**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Philpott et al.[^32^](#alr22624-bib-0032){ref-type="ref"} (2017)      Randomized, double‐blind, placebo‐ controlled trial               1                    26/55                  Sodium citrate sprayPlacebo                                                                                                                                                                                                            9% intranasal sodium citrate spray 0.5 mL in each nasal cavitySterile water placebo 0.5 mL in each nasal cavity             120 minutes     Olfactory thresholds  Temporary improvement for all patients in detection threshold for 3 of 4 odorants after administration of intranasal sodium citrate
  Whitcroft et al.[^33^](#alr22624-bib-0033){ref-type="ref"} (2016)     Prospective, controlled trial                                     2                    7/57                   Sodium citrate sprayPlacebo                                                                                                                                                                                                            9% intranasal sodium citrate spray 1 mL in 1 nasal cavitySodium chloride placebo solution 1 mL in contralateral side       20‐30 minutes      Sniffin' Sticks     Significant improvement in identification scores for PVOD patients (*p* = 0.02)
  Whitcroft et al.[^34^](#alr22624-bib-0034){ref-type="ref"} (2017)     Prospective, single‐blind, internally‐controlled trial            3                    49/49                  Sodium citrate sprayPlacebo                                                                                                                                                                                                            2.5% intranasal sodium citrate spray 1 mL in 1 nasal cavitySodium chloride placebo solution 1 mL in contralateral side     20‐30 minutes      Sniffin' Sticks     Significant improvement in composite threshold and identification scores for patients receiving sodium citrate compared to placebo (*p* = 0.04)
  **Insulin**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Schopf et al.[^35^](#alr22624-bib-0035){ref-type="ref"} (2015)        Prospective, controlled pilot study                               4                    10/10                  InsulinPlacebo                                                                                                                                                                                                                         Intranasal insulin 40 IU total (0.2 mL/nasal cavity)Saline placebo (0.2 mL/nasal cavity)                                     55 weeks         Sniffin' Sticks     Immediate (short term) improvement of threshold and discrimination (D), but not able to compare this improvement vs placebo effect due to small sample sizePatients with higher BMI performed better on odor identification tasks (*p* = 0.005)

BTT = butanol threshold test; CCCRC = Connecticut Chemosensory Clinical Research Center test; IU = international units; LOE = level of evidence; PVOD = post‐viral olfactory dysfunction; TDI = threshold, discrimination, and identification score; T&T = Toyota & Takagi olfactometer; VAS = visual analog scale.
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The remaining 3 studies were all level 4 evidence with no control groups, with the largest cohort of PVOD patients (n = 244) studied by Mori et al.[^28^](#alr22624-bib-0028){ref-type="ref"} This study was limited by its retrospective nature and did not detail the specific topical corticosteroids or average time for follow‐up; in this setting, it is difficult to interpret the "slight improvement," "improvement," or "cured" nature of OD found in 57.8% of their PVOD patients. All 133 patients in the case series by Fukazawa et al. had a PVOD etiology of OD, with improvement seen in 49.6% of patients using T&T olfactometry, and an average improvement of 10.2 to 39.5 points on VAS, after injection of dexamethasone or betamethasone into the olfactory cleft.[^30^](#alr22624-bib-0030){ref-type="ref"} Fleiner and Goktas utilized a directed beclomethasone spray therapy and demonstrated that 2/8 PVOD patients had TDI score improvement of greater than 6 points.[^31^](#alr22624-bib-0031){ref-type="ref"}

**Summary**: topical or local steroid therapy **Aggregate evidence**: C (Level 1: 1 study, Level 4: 3 studies)**Benefit**: Improved TDI and T&T scores**Harm**: Minimal treatment‐related side effects (eg, local irritation, possible epistaxis), minor inconvenience**Cost**: Minimal**Benefit‐Harm assessment**: Balance of benefit and harm**Value judgments**: Heterogeneous studies and difficult to interpret Level 1 study secondary to prior usage of systemic steroids make providing a recommendation challenging given minimal likely benefit in conjunction with the minimal harm.**Recommendation level**: Option**Intervention**: Low risk intervention, with potential improved olfaction, but potential benefit is also limited. Can be offered to patients with PVOD, but if no initial improvement, limited evidence suggesting benefit with chronic use.

### Nonsteroidal topical therapies {#alr22624-sec-0170}

In regard to nonsteroidal topical therapies (Table [7](#alr22624-tbl-0007){ref-type="table"}), 3 studies investigated intranasal sodium citrate.[^32^](#alr22624-bib-0032){ref-type="ref"}, [^33^](#alr22624-bib-0033){ref-type="ref"}, [^34^](#alr22624-bib-0034){ref-type="ref"} Philpott et al. conducted a double‐blinded, randomized, placebo‐controlled trial of 55 patients with nonconductive OD, the majority of which had PVOD (42%) or idiopathic loss (26%).[^32^](#alr22624-bib-0032){ref-type="ref"} Though subgroup analyses for patients with PVOD was not completed, there was a significant improvement in 3 of the 4 odor thresholds in the intervention arm compared to the control arm (*p* \< 0.05). Two additional studies utilizing intranasal sodium citrate performed by Whitcroft et al. used Sniffin' Sticks to evaluate objective olfactory outcomes. The first prospective, controlled trial demonstrated significant improvement in 7 patient\'s odor identification scores (p = 0.02), but no change in odor threshold scores (*p* = 0.08) in the treatment group compared to placebo.[^33^](#alr22624-bib-0033){ref-type="ref"} A follow‐up, prospective, single‐blind, internally‐controlled study comprised exclusively of patients with PVOD identified significant improvement in composite threshold and identification scores compared to placebo (*p* = 0.04), but no change in odor identification or threshold compared to placebo (*p* = 0.11 and *p* = 0.23, respectively).[^34^](#alr22624-bib-0034){ref-type="ref"} Composite TDI scores were not calculated.

Despite commonalities in treatment modality and dosages across these 3 placebo‐controlled studies, key differences must be acknowledged. While the RCT utilized bilateral sodium citrate spray versus sterile water placebo, the 2 studies by Whitcroft et al. had each patient serve as their own control‐sodium citrate spray applied to 1 nasal cavity and saline solution to the other.[^33^](#alr22624-bib-0033){ref-type="ref"}, [^34^](#alr22624-bib-0034){ref-type="ref"} The choice to use sterile water as the control agent instead of saline was acknowledged by Philpott et al., describing that the ionic composition of saline could have a local influence on the sodium ion concentrations involved with olfaction.[^32^](#alr22624-bib-0032){ref-type="ref"} Additionally, timing of olfactory testing differed in these studies. Philpott et al. demonstrated peak effect of sodium citrate at 30 to 60 minutes after application;[^32^](#alr22624-bib-0032){ref-type="ref"} however, both Whitcroft studies evaluated olfaction only 20 to 30 minutes after treatment.[^33^](#alr22624-bib-0033){ref-type="ref"}, [^34^](#alr22624-bib-0034){ref-type="ref"} How these findings translate to longer, clinically relevant outcomes, is unclear. Across all studies, sodium citrate spray was well tolerated, with common side effects including transient rhinorrhea, sore throat, and nasal obstruction.

Furthermore, 1 identified study investigated intranasal insulin compared to saline placebo.[^35^](#alr22624-bib-0035){ref-type="ref"} Despite a small sample size of 10 PVOD patients, their findings supported increased odor intensity perception (*p* = 0.043) after intranasal insulin compared to placebo. Interestingly, there was a significant correlation between BMI and identification scores following administration of insulin (*ρ* = 0.909, *p* = 0.005). As this is a single pilot study, there is insufficient evidence for it to be included in the evidence‐based summary.

**Summary**: intranasal sodium citrate **Aggregate evidence**: B (Level 1: 1 study, Level 2: 1 study, Level 3: 1 study)**Benefit**: Short‐term and temporary improvement of post‐treatment objective olfactory measures**Harm**: Minimal, including transient rhinorrhea, sore throat, and nasal congestion**Cost**: Minimal**Benefit‐Harm assessment**: Balance of benefit and harm**Value judgments**: Though the level of evidence and rigor of these studies demonstrate promise for intranasal sodium citrate, the transient nature and short‐term follow‐up of these studies makes the prolonged clinical utility of these medications difficult to determine, but certainly further study is warranted.**Recommendation level**: Option**Intervention**: Likely a low risk intervention with demonstrated temporary improved olfaction, but long‐term benefit is unclear. Assessment of long‐term benefit is necessary before more definitive clinical recommendations can be made.

Nonsteroidal oral medications {#alr22624-sec-0180}
-----------------------------

Numerous nonsteroidal oral medications have been evaluated for treatment of OD, primarily composed of vitamins and antioxidants (Table [8](#alr22624-tbl-0008){ref-type="table"}). Antibiotics, phosphodiesterase inhibitors, and muscle relaxants have also been investigated. Though these therapies do not belong to the same treatment class, these medications benefit from wide accessibility and are generally well‐tolerated.

###### 

Summary of nonsteroidal oral medication studies

+----------------------------------------------------------------+---------------------------------------------------------------------------+-----+--------------------------------------+-------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------+---------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Author (year)                                                  | Study design                                                              | LOE | PVOD subjects (n)/Total subjects (n) | Primary comparison                                                                                          | Treatment details                                                                                                                                                                                                          | Follow‐up                           | Olfactory outcome   | Results                                                                                                                                                                                                                                                                                                                                                                                          |
+:===============================================================+:==========================================================================+:===:+:====================================:+:============================================================================================================+:===========================================================================================================================================================================================================================+:===================================:+:====================+:=================================================================================================================================================================================================================================================================================================================================================================================================+
| **Antibiotics**                                                |                                                                           |     |                                      |                                                                                                             |                                                                                                                                                                                                                            |                                     |                     |                                                                                                                                                                                                                                                                                                                                                                                                  |
+----------------------------------------------------------------+---------------------------------------------------------------------------+-----+--------------------------------------+-------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------+---------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Reden et al.[^36^](#alr22624-bib-0036){ref-type="ref"} (2011)  | Double blinded, randomized, placebo‐controlled trial                      | 1   | 55/55                                | MinocyclinePlacebo                                                                                          | Minocycline 100 mg twice daily                                                                                                                                                                                             | 207 days                            | Sniffin' Sticks     | No difference in TDI between minocycline and placebo (*p* = 0.55)                                                                                                                                                                                                                                                                                                                                |
+----------------------------------------------------------------+---------------------------------------------------------------------------+-----+--------------------------------------+-------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------+---------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Wang et al.[^37^](#alr22624-bib-0037){ref-type="ref"} (2018)   | Retrospective cohort study                                                | 3   | 158/288                              | Bacteriostatic or bactericidal antibioticNo antibiotic                                                      | Antibiotic: either bacteriostatic or bactericidal                                                                                                                                                                          | Bactericidal antibiotics: 178 days  | UPSIT               | No overall effect of antibiotic treatment on composite UPSIT scoresImproved odor detection thresholds after bactericidal vs. bacteriostatic antibiotics in PVOD patients (*p* = 0.023)                                                                                                                                                                                                           |
|                                                                |                                                                           |     |                                      |                                                                                                             |                                                                                                                                                                                                                            |                                     |                     |                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                                |                                                                           |     |                                      |                                                                                                             |                                                                                                                                                                                                                            | Bacteriostatic antibiotic: 163 days |                     |                                                                                                                                                                                                                                                                                                                                                                                                  |
+----------------------------------------------------------------+---------------------------------------------------------------------------+-----+--------------------------------------+-------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------+---------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Theophylline**                                               |                                                                           |     |                                      |                                                                                                             |                                                                                                                                                                                                                            |                                     |                     |                                                                                                                                                                                                                                                                                                                                                                                                  |
+----------------------------------------------------------------+---------------------------------------------------------------------------+-----+--------------------------------------+-------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------+---------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Henkin et al.[^39^](#alr22624-bib-0039){ref-type="ref"} (2017) | Prospective case‐control trial                                            | 3   | 10/44                                | Theophylline (all)                                                                                          | Oral theophylline 200‐800 mg                                                                                                                                                                                               | 2‐10 months                         | Olfactometry, VAS   | 61% of all patients reported improvement in subjective smell after treatment                                                                                                                                                                                                                                                                                                                     |
+----------------------------------------------------------------+---------------------------------------------------------------------------+-----+--------------------------------------+-------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------+---------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Henkin et al.[^38^](#alr22624-bib-0038){ref-type="ref"} (2009) | Prospective case series                                                   | 4   | 97/312                               | Theophylline (all)                                                                                          | Oral extended release theophylline in divided doses 200‐800 mg daily                                                                                                                                                       | Up to 72 months                     | Olfactometry, VAS   | Subjective improvement in 50.3% patients of all etiologies, with 21.7% returning to normalDetection and recognition thresholds improved significantly at each drug dosage, with greater improvement at 600/800 mg doses than 200/400 mg doses                                                                                                                                                    |
+----------------------------------------------------------------+---------------------------------------------------------------------------+-----+--------------------------------------+-------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------+---------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| **Supplements: vitamins and antioxidants**                     |                                                                           |     |                                      |                                                                                                             |                                                                                                                                                                                                                            |                                     |                     |                                                                                                                                                                                                                                                                                                                                                                                                  |
+----------------------------------------------------------------+---------------------------------------------------------------------------+-----+--------------------------------------+-------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------+---------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Reden et al.[^44^](#alr22624-bib-0044){ref-type="ref"} (2012)  | Double blinded, randomized, placebo‐controlled trial                      | 1   | 33/52                                | Vitamin APlacebo                                                                                            | Vitamin A 10,000 IU daily                                                                                                                                                                                                  | 5 months                            | Sniffin' Sticks     | No difference in TDI improvement between vitamin A and placebo for all etiologies (*p* = 0.47)                                                                                                                                                                                                                                                                                                   |
+----------------------------------------------------------------+---------------------------------------------------------------------------+-----+--------------------------------------+-------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------+---------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Henkin et al.[^40^](#alr22624-bib-0040){ref-type="ref"} (1976) | Double blinded, randomized, placebo‐controlled crossover clinical trial   | 1   | 45/106                               | Zinc sulfatePlacebo                                                                                         | Zinc sulfate 100 mg daily for 6 monthsZinc sulfate 100 mg daily for 3 months followed by placebo daily for 3 monthsPlacebo daily for 3 months followed by zinc sulfate 100 mg daily for 3 monthsPlacebo daily for 6 months | 3 and 6 months                      | Olfactometry, VAS   | No statistically significant difference in mean changes in smell thresholds between baseline and 3 or 6 months for any group                                                                                                                                                                                                                                                                     |
+----------------------------------------------------------------+---------------------------------------------------------------------------+-----+--------------------------------------+-------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------+---------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Quint et al.[^42^](#alr22624-bib-0042){ref-type="ref"} (2002)  | Prospective, controlled trial                                             | 2   | 38/77                                | CaroverineZinc sulfate                                                                                      | Caroverine 120 mg dailyZinc sulfate 400 mg daily                                                                                                                                                                           | 4 weeks                             | Sniffin' Sticks     | Improvement in threshold (*p* = 0.005) and identification (*p* = 0.042) scores of anosmic patients of all etiologies with caroverineImprovement in identification (*p* = 0.041) scores of hyposmic patients of all etiologies with caroverine                                                                                                                                                    |
+----------------------------------------------------------------+---------------------------------------------------------------------------+-----+--------------------------------------+-------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------+---------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Aiba et al.[^41^](#alr22624-bib-0041){ref-type="ref"} (1998)   | Retrospective, non‐blinded, non‐controlled parallel group, clinical trial | 3   | 184/426                              | Zinc sulfateZinc sulfate + topical corticosteroid spray + vitamin BTopical corticosteroid spray + vitamin B | Zinc sulfate 300 mg dailyTopical steroid (not otherwise specified)Vitamin B (not otherwise specified)                                                                                                                      | \>2 weeks                           | Subjective symptoms | No significant differences among the 3 treatment groups for PVOD patients                                                                                                                                                                                                                                                                                                                        |
+----------------------------------------------------------------+---------------------------------------------------------------------------+-----+--------------------------------------+-------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------+---------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Hummel et al.[^45^](#alr22624-bib-0045){ref-type="ref"} (2002) | Non‐blinded, non‐controlled prospective case series                       | 4   | 23/23                                | Alpha‐lipoic acid (all)                                                                                     | Alpha‐lipoic acid 600 mg daily                                                                                                                                                                                             | 3‐11 months                         | Sniffin' Sticks     | Significant improvement in olfactory function following treatment (pre‐treatment mean: 21.05, post‐treatment mean: 24.58; *p* = 0.002)Younger age associated with better outcomes (*p* = 0.018)Duration of OD had no effect on improvement (*p* = 0.52)                                                                                                                                          |
+----------------------------------------------------------------+---------------------------------------------------------------------------+-----+--------------------------------------+-------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------+---------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Duncan et al.[^43^](#alr22624-bib-0043){ref-type="ref"} (1962) | Non‐controlled case series                                                | 4   | 21/56                                | Vitamin A (all)                                                                                             | Vitamin A 100,000 IU/mL injectable preparation weekly followed by 50,000‐150,000 IU oral tablets/emulsions daily for 3‐12 weeks                                                                                            | Not listed                          | Subjective symptoms | 35/52 patients receiving vitamin A injection as initial treatment experienced complete improvement in olfaction, 11/52 experienced partial improvement and 6/52 patients had no improvement2/3 patients with vitamin A tablets as initial treatment had marked improvement; 1/3 had perceptible improvement1/1 patients with vitamin A oral emulsion as initial treatment had marked improvement |
+----------------------------------------------------------------+---------------------------------------------------------------------------+-----+--------------------------------------+-------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-------------------------------------+---------------------+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+

IU = international units; LOE = level of evidence; OD = olfactory dysfunction; PVOD = post‐viral olfactory dysfunction; TDI = threshold, discrimination, and identification score; UPSIT = University of Pennsylvania Smell Identification Test; VAS = visual analog scale.
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In regard to antibiotic treatment, 1 RCT of 55 patients with PVOD studying minocycline demonstrated that the medication was well tolerated, but there was no difference in overall TDI scores between the group receiving minocycline and the group receiving the placebo (*p* = 0.55).[^36^](#alr22624-bib-0036){ref-type="ref"} Another study retrospectively assessed various antibiotics and similarly found no overall improvement in UPSIT scores after treatment; however, patients with PVOD had significantly improved odor detection thresholds after treatment with bactericidal antibiotics relative to patients who received bacteriostatic antibiotics or no treatment (*p* = 0.023).[^37^](#alr22624-bib-0037){ref-type="ref"} The study did not mention which antibiotics were evaluated or the duration.

Additionally, theophylline, a bronchodilator typically reserved for chronic respiratory disease, was investigated in 2 studies.[^38^](#alr22624-bib-0038){ref-type="ref"}, [^39^](#alr22624-bib-0039){ref-type="ref"} Both were prospective evaluations by Henkin et al. using oral theophylline doses between 200‐800 mg: the first a case series and the second a case‐control trial. Both reports demonstrated an overall improved subjective sense of smell, as well as detection and recognition thresholds following treatment.[^38^](#alr22624-bib-0038){ref-type="ref"}, [^39^](#alr22624-bib-0039){ref-type="ref"} There was no comparison group in either study.

Six total studies investigated oral supplements, with 3 on zinc sulfate,[^40^](#alr22624-bib-0040){ref-type="ref"}, [^41^](#alr22624-bib-0041){ref-type="ref"}, [^42^](#alr22624-bib-0042){ref-type="ref"} 2 on Vitamin A,[^43^](#alr22624-bib-0043){ref-type="ref"}, [^44^](#alr22624-bib-0044){ref-type="ref"} and 1 on alpha‐lipoic acid.[^45^](#alr22624-bib-0045){ref-type="ref"} One RCT from 1976 found no significant difference in olfactory thresholds between patients who received 100 mg zinc sulfate daily compared to placebo, at 3 or 6‐month follow‐up.[^40^](#alr22624-bib-0040){ref-type="ref"} Similar results were demonstrated by Aiba et al. when comparing 300 mg zinc sulfate to zinc sulfate in combination with topical corticosteroids and vitamin B.[^41^](#alr22624-bib-0041){ref-type="ref"} A third study by Quint et al. intended to investigate the efficacy of caroverine, a quinoxaline derivate and NMDA antagonist, used a group of patients receiving zinc sulfate as the control group in a cohort of patients with a mixed etiology of OD.[^42^](#alr22624-bib-0042){ref-type="ref"} While caroverine was associated with improved odor thresholds (*p* = 0.005) and identification (*p* = 0.042) in anosmic patients and improved identification in hyposmic patients (*p* = 0.041), zinc sulfate did not have a significant effect on thresholds or identification in either anosmic or hyposmic patients (*p* = 0.10, *p* = 0.428 respectively). Specific comparative analyses for PVOD patients in each treatment group could not be fully captured, though thresholds became measurable in 13 anosmic patients after caroverine treatment, of which 6 (46%) had PVOD.

In regard to vitamin A, a case series conducted by Duncan et al. in 1962 reported improvement in subjective olfactory function.[^43^](#alr22624-bib-0043){ref-type="ref"} Though "marked improvement" was described in 35 of 52 patients with OD of various etiologies, there was no standardized treatment protocol or dosage described. Decades later, a double‐blinded, randomized, placebo‐controlled trial by Reden et al. examined the utility of 10,000 IU of Vitamin A daily for 3 months compared to placebo for the treatment of PVOD.[^44^](#alr22624-bib-0044){ref-type="ref"} While TDI scores increased significantly in all patients (*p* \< 0.001), there was no significant difference between the placebo and treatment groups (*p* = 0.47).

Furthermore, alpha‐lipoic acid, typically used to treat diabetic neuropathy, was investigated by Hummel et al. in 23 non‐blinded patients with PVOD.[^45^](#alr22624-bib-0045){ref-type="ref"} TDI scores significantly improved after an average of 4.5 months on 600 mg/day alpha‐lipoic acid (pre‐treatment mean: 21.05, post‐treatment mean: 24.58; *p* = 0.002), though they did not reach an MCID for the Sniffin' Sticks instrument. While the duration of PVOD did not appear to influence outcomes, patients under 60 years of age had improved recovery as compared to those older than 60 years old (*p* = 0.018). All patients received the intervention; there was no comparison group. This is in contrast to several other studies, including those by Heilmann et al., Fleiner and Goktas, and Mori et al., who reported no correlation between olfactory outcome and patient age in their patient cohorts.[^24^](#alr22624-bib-0024){ref-type="ref"}, [^28^](#alr22624-bib-0028){ref-type="ref"}, [^31^](#alr22624-bib-0031){ref-type="ref"}

Because of the heterogeneity in this treatment type, we elected to summarize oral zinc sulfate independently from the other treatments that each totaled no \>2 investigations.

**Summary**: oral zinc sulfate **Aggregate evidence**: B (Level 1: 1 study, Level 2: 1 study, Level 3: 1 study)**Benefit**: no studies demonstrating improved olfactory outcomes**Harm**: no reported therapy‐related risks, though zinc toxicity is plausible**Cost**: medication cost**Benefit‐Harm assessment**: Preponderance of harm over benefit**Value judgments**: None**Recommendation level**: Recommendation against

**Summary**: oral antibiotics, theophylline, vitamin A, caroverine, alpha‐lipoic acid **Aggregate evidence**: D Level 1: 2 studies, Level 2: 1 study, Level 3: 2 studies, Level 4: 3 studies**Benefit**: improvement TDI scores, olfactometry, and subjective scores**Harm**: minimal side effects of medications reported, but not rigorously assessed in all studies**Cost**: minimal to moderate depending on cost of medication, many available without prescription**Benefit‐Harm assessment**: balance of benefit and harm**Value judgments**: An assortment of studies examining different medications, completed with varying degrees of rigor and quality. Despite several studies with encouraging results, interpretation of this collection of studies is challenging, though trials with promising outcomes likely warrant further study (eg, alpha‐lipoic acid).Recommendation level: No recommendation

Olfactory training {#alr22624-sec-0190}
------------------

Ten total studies assessed olfactory training (OT), with 2 level 1 studies, 2 level 2 studies, 3 level 3 studies, and 3 level 4 studies (Table [9](#alr22624-tbl-0009){ref-type="table"}).[^46^](#alr22624-bib-0046){ref-type="ref"}, [^47^](#alr22624-bib-0047){ref-type="ref"}, [^48^](#alr22624-bib-0048){ref-type="ref"}, [^49^](#alr22624-bib-0049){ref-type="ref"}, [^50^](#alr22624-bib-0050){ref-type="ref"}, [^51^](#alr22624-bib-0051){ref-type="ref"}, [^52^](#alr22624-bib-0052){ref-type="ref"}, [^53^](#alr22624-bib-0053){ref-type="ref"}, [^54^](#alr22624-bib-0054){ref-type="ref"} All but 1 study used Sniffin' Sticks to test olfactory outcomes, with the other using UPSIT. Most studies employed an OT protocol involving exposure to 4 odors twice daily for at least 12 weeks.[^46^](#alr22624-bib-0046){ref-type="ref"}

###### 

Summary of olfactory training studies

  Author (year)                                                            Study design                                                     LOE   PVOD subjects (n)/Total subjects (n)  Primary comparison                                                                                                            Treatment details                                                                                                                                                                                    Follow‐up                  Olfactory outcome            Results
  ------------------------------------------------------------------------ --------------------------------------------------------------- ----- -------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- -------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nguyen and Patel.[^54^](#alr22624-bib-0054){ref-type="ref"} (2018)       Randomized control trial                                          1                   62/133                 Olfactory training + budesonide irrigationOlfactory training + saline irrigation                                              Exposure to 4 odors twice daily for 6 monthsBudesonide 0.5 mg BID for 6 months                                                                                                                        6 months                        UPSIT                  Budesonide irrigations + OT is superior to OT alone (adjusted OR 3.93)Younger age (*p* \< 0.0001) and shorter duration of olfactory loss (*p* \< 0.0001) associated with better outcomes
  Damm et al.[^49^](#alr22624-bib-0049){ref-type="ref"} (2014)             Randomized, single‐blind, controlled crossover clinical trial     1                  144/144                 Training with high concentration odorantsTraining with low concentration odorantsCrossover in treatment regimen at 18 weeks   Exposure to 4 odors twice daily using commercially available felt‐tip pensExposure to 4 odors twice daily of concentration at the 10th percentile of healthy volunteers' threshold                18 and 36 weeks      Sniffin' Sticks, subjective symptoms  For all patients, no difference in rates of TDI improvement ≥6 seen between 2 groups at 18 weeks (*p* = 0.11) or 36 weeks (after crossover, *p* = 0.073)For patients with PVOD \<12 months, high concentration training produced better olfactory results (*p* = 0.03)Shorter duration of PVOD associated with better outcomes (*p* = 0.03)
  Konstantinidis et al.[^52^](#alr22624-bib-0052){ref-type="ref"} (2016)   Prospective, randomized controlled trial                          2                  111/111                 Long‐term training groupShort‐term training groupControl group                                                                Exposure to 4 odors twice daily OT for 56 weeksOT for 16 weeksNo treatment                                                                                                                            56 weeks                   Sniffin' Sticks             Long‐term training produces better outcomes than short‐term training (mean TDI short term: 24.1 ± 1.5 from 15 ± 2.2 baseline, long term: 27.3 ± 1.5 from 15.9 ± 2.2 baseline; *p* = 0.038 at 56 weeks)Both OT regimens produced improved olfactory function compared with placebo (TDI 20.5 ± 1.6 from 15.2 ± 1.8 at baseline, *p* = 0.005 at 56 weeks)No effect of gender, age, or severity of olfactory loss on improvement. Shorter duration of olfactory loss is associated with higher chance of improvement
  Altundag et al.[^51^](#alr22624-bib-0051){ref-type="ref"} (2015)         Prospective, randomized, controlled clinical trial                2                   85/85                  Classical olfactory trainingModified olfactory trainingControl group                                                          Exposure to 4 odors twice daily for 36 weeksExposure to 4 odors twice daily for 12 weeks, followed by 4 different odors for 12 weeks, followed by 4 different odors for 12 weeksNo treatment    12, 24, and 36 weeks             Sniffin' Sticks             Higher TDI scores in MOT and COT groups compared to controls (*p* ≤ 0.05) at all timepoints.Higher mean TDI scores in MOT group compared to COT (26.3 ± 0.7 vs 24.3 ± 0.6, *p* = 0.034 at 36 weeks)^a^Shorter duration of olfactory loss associated with greater improvement in TDI for all patients (*p* \< 0.001)
  Poletti et al.[^53^](#alr22624-bib-0053){ref-type="ref"} (2017)          Prospective, pseudo‐randomized trial                              3                   70/96                  Training with low molecular weight odorantsTraining with high molecular weight odorants                                       Exposure to 3 odors twice in the morning and twice in the evening Low molecular weight odorants \<150 g/molHigh molecular weight odorants \>150 g/mol                                                 5 months                   Sniffin' Sticks             For PVOD patients, training with high molecular weight molecules produced significantly improved PEA threshold compared to low molecular weight molecules (*p* = 0.004)
  Konstantinidis et al.[^48^](#alr22624-bib-0048){ref-type="ref"} (2013)   Prospective controlled trial                                      3                   81/119                 Olfactory trainingControl group                                                                                               Exposure to 4 odors twice dailyNo treatment                                                                                                                                                        8 and 16 weeks                Sniffin' Sticks             TDI improvement ≥6 seen in 67.8% of PVOD patients undergoing OT vs. 33% of PVOD controls (*p* \< 0.05)No impact of age or gender, but shorter duration of olfactory loss associated better prognosis
  Hummel et al.[^46^](#alr22624-bib-0046){ref-type="ref"} (2009)           Prospective controlled, nonblinded trial                          3                   35/56                  Olfactory trainingControl group                                                                                               Exposure to 4 odors twice dailyNo treatment                                                                                                                                                           12 weeks                   Sniffin' Sticks             Patients undergoing OT exhibited significantly higher scores than patients who did not train (*p* = 0.031) (whole cohort)10/36 patients undergoing OT exhibited TDI improvement of ≥6. Of these 10, 5 were PVOD patients
  Geißler et al.[^50^](#alr22624-bib-0050){ref-type="ref"} (2014)          Prospective, nonrandomized case series                            4                   39/39                  Olfactory training (all)                                                                                                      Exposure to 4 odors twice daily                                                                                                                                                                   16 and 32 weeks                Sniffin' Sticks             At 32 weeks, mean TDI score significantly increased compared to baseline (21 ± 7 from 17 ± 5, *p* = 0.021). 79% of patients showed improvement in TDI scoreAt 32 weeks, odor discrimination score improved (*p* = 0.004). No change in threshold (*p* = 1.0) or identification (*p* = 0.431) scoreAge (*p* = 0.921), gender (*p* = 0.611) and duration (*p* = 0.540) of olfactory loss had no influence on TDI improvement
  Kollndorfer et al.[^55^](#alr22624-bib-0055){ref-type="ref"} (2014)      Prospective case series                                           4                    7/7                   Olfactory training (all)                                                                                                      Exposure to 4 odors twice daily                                                                                                                                                                       13 weeks                   Sniffin' Sticks             Statistically significant improvement in threshold scores, from 1.39 ± 0.61 to 3.07 ± 1.98 (*p* = 0.028), but no change in TDI, discrimination or identification scoresEnhanced organization of functional neural connectivity to piriform cortices on functional magnetic resonance imaging following OT
  Fleiner et al.[^47^](#alr22624-bib-0047){ref-type="ref"} (2012)          Retrospective case series                                         4                   16/16                  Olfactory trainingOlfactory training + topical corticosteroids                                                                Exposure to 4 odors twice dailyTopical corticosteroid treatment not specified                                                                                                                      4 and 8 months                Sniffin' Sticks             All PVOD patients experienced significant increase in TDI score at 4 months (20.83 ± 5.86 from 15.56 ± 6.90, *p* = 0.02)All PVOD patients demonstrated improved odor identification scores compared to baseline at both follow‐up visits (*p* = 0.02). No significant change in threshold or discrimination scoresAt 4‐month follow‐up, TDI increase ≥6 seen in 1/9 PVOD patients undergoing OT only compared to 1/7 PVOD patients in the OT + steroid groupAt 8‐month follow‐up, TDI increase ≥6 seen in 1/9 PVOD patients undergoing OT only compared to 4/7 PVOD patients in the OT + steroid group.No association between olfactory function with age or gender at follow‐up

Data presented as mean ± standard deviation unless otherwise specified.

mean ± standard error of the mean.

COT = classical olfactory training; LOE = level of evidence; MOT = modified olfactory training; PEA = phenyl ethyl alcohol; PVOD = post‐viral olfactory dysfunction; TDI = threshold, discrimination, and identification score; UPSIT = University of Pennsylvania Smell Identification Test.
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This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

In 4 studies comparing OT to no treatment, OT was found to have statistically superior olfactory outcomes.[^46^](#alr22624-bib-0046){ref-type="ref"}, [^48^](#alr22624-bib-0048){ref-type="ref"}, [^51^](#alr22624-bib-0051){ref-type="ref"}, [^52^](#alr22624-bib-0052){ref-type="ref"} Two of these studies in particular had multiple treatment groups of solely PVOD patients: Altundag et al. compared a classical olfactory training (COT) group (36 weeks of OT) to a modified olfactory training (MOT) group (3 sets of 12 weeks of OT with different odors),[^51^](#alr22624-bib-0051){ref-type="ref"} and Konstantinidis et al. compared a long‐term training group (56 weeks) to a short‐term training group (16 weeks).[^52^](#alr22624-bib-0052){ref-type="ref"} Though the former study did not find significant differences in composite TDI score between the MOT and COT groups at 24 or 36 weeks, the MOT group had significantly better odor discrimination and odor identification scores at these time points.[^51^](#alr22624-bib-0051){ref-type="ref"} The latter study concluded that long‐term training was superior to short‐term training with a significantly higher average TDI score at 56 weeks (short term: 24.1 ± 1.5 from 15 ± 2.2 baseline, long term: 27.3 ± 1.5 from 15.9 ± 2.2 baseline; *p* = 0.038), though both training groups showed the most olfactory improvement within the first 16 weeks.[^52^](#alr22624-bib-0052){ref-type="ref"} Interestingly, both studies commented that a shorter duration of olfactory loss prior to treatment initiation was associated with greater improvement in olfactory function after OT treatment. In a crossover RCT, Damm et al. demonstrated greater improvement in OT with high concentration odors compared to low‐concentration odors in patients with a duration of PVOD less than 12 months (*p* = 0.03).[^49^](#alr22624-bib-0049){ref-type="ref"}

Just as Damm et al. studied different concentrations of the odors used in OT,[^49^](#alr22624-bib-0049){ref-type="ref"} Poletti et al. conducted a prospective, pseudo‐randomized trial in which patients underwent OT with either low molecular weight (\<150 g/mol) or high molecular weight (\>150 g/mol) odorants. In this study, they concluded that high molecule weight odorants (eg, ethyl vanilline) were superior in improving the phenyl ethyl alcohol (PEA) threshold relative to low molecular weight odorants (eg, ethyl maltol) in PVOD patients (*p* = 0.004).[^53^](#alr22624-bib-0053){ref-type="ref"} Nguyen and Patel also attempted to optimize the OT protocol with a RCT comparing OT with budesonide irrigation compared to OT with saline irrigation.[^54^](#alr22624-bib-0054){ref-type="ref"} Though this study did not perform subgroup analysis for PVOD patients, they found that 43.9% of patients had olfactory improvement with budesonide irrigation and OT compared to 26.9% of controls (*p* = 0.039); additionally, a shorter duration of olfactory loss was significantly associated with olfactory improvement (p \< 0.0001).[^54^](#alr22624-bib-0054){ref-type="ref"} Interestingly, even in absence of robust TDI score improvement, Kollndorfer et al. demonstrated enhanced organization of neural connectivity to the piriform cortices on functional magnetic resonance imaging following traditional OT.[^55^](#alr22624-bib-0055){ref-type="ref"}

Overall, OT was found to improve olfactory functioning in all 10 studies. Higher concentrations and molecular weights of the odors, longer duration of OT, and a variety of odors used for OT found to be most helpful in improving olfactory function. A shorter duration of OD prior to initiation of OT was also repeatedly associated with better olfactory function outcomes.

**Summary**: **Aggregate evidence**: B (Level 1: 2 studies, Level 2: 2 studies, Level 3: 3 studies, Level 4: 3 studies)**Benefit**: Improved Sniffin' Sticks and UPSIT scores**Harm**: minimal, inconvenience of daily training**Cost**: Minimal with good access to training kits, though in countries with limited proprietary kits available, costs may be increased.**Benefit‐Harm assessment**: Preponderance of benefit over harm**Value judgments**: Given that this is an inexpensive option with minimal/no harm and likely benefit, the value of this option is high.**Recommendation level**: Recommendation**Intervention**: Begin OT following identification of patient with lasting PVOD. Consider augmenting OT with topical budesonide therapy, however further investigation into optimal OT treatment protocol is warranted.

Acupuncture {#alr22624-sec-0200}
-----------

Traditional Chinese acupuncture (TCA) was evaluated as a treatment for PVOD in 2 level 4 studies after failure to respond to 1 to 6 months of oral steroids, vitamin B, olfactory training, or topical steroids (Table [10](#alr22624-tbl-0010){ref-type="table"}).[^56^](#alr22624-bib-0056){ref-type="ref"}, [^57^](#alr22624-bib-0057){ref-type="ref"} Vent et al. demonstrated an increase in mean TDI score from 13.5 to 17.9 after TCA.[^57^](#alr22624-bib-0057){ref-type="ref"} Additionally, 8/15 patients attained an increase in TDI score of ≥6 points (MCID), significantly improved compared to controls receiving vitamin B complex (*p* = 0.02).[^57^](#alr22624-bib-0057){ref-type="ref"} Dai et al. produced similar results, with 11/25 patients in the TCA group having improved olfactory function compared to 4/25 in the no treatment group (*p* = 0.031).[^56^](#alr22624-bib-0056){ref-type="ref"} Frequency of TCA treatment differed between these 2 studies, and neither paper reported any adverse events related to TCA.

###### 

Summary of acupuncture studies

  Author (year)                                                  Study design                                                      LOE   PVOD subjects (n)/Total subjects (n)  Primary comparison                                 Treatment details                                                                                                                     Follow‐up   Olfactory outcome  Results
  -------------------------------------------------------------- ---------------------------------------------------------------- ----- -------------------------------------- -------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ ----------- ------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Dai et al.[^56^](#alr22624-bib-0056){ref-type="ref"} (2016)    Randomized, nonblinded controlled trial                            3                   50/50                  Traditional Chinese acupunctureControl group       20 minutes of acupuncture 3 times per week for a course of 10 times, with 3‐5 days of rest between courses, continued for 3 months    3 months          UPSIT        11/25 patients in TCA group showed improved olfactory function vs. 4/25 in the observation group (*p* = 0.031)No significant differences between groups in recovery associated with age (*p* = 0.122), gender (*p* = 0.527), or duration of disease (*p* = 0.948)
  Vent et al.[^57^](#alr22624-bib-0057){ref-type="ref"} (2010)   Retrospective nonblinded, non‐controlled, parallel group trial     4                   15/15                  Traditional Chinese acupunctureVitamin B complex   30 minutes of acupuncture weekly for 10 weeksVitamin B complex for 12 weeks                                                           12 weeks     Sniffin' Sticks   TDI score increase significantly better with TCA treatment (17.9 ± 6.5 from 13.5 ± 5.4) compared to vitamin B complex (15.8 ± 4.8 from 13.0 ± 3.5, *p* = 0.02)

Data presented as mean ± standard deviation.

LOE = level of evidence; PVOD = post‐viral olfactory dysfunction; TCA = traditional Chinese acupuncture; UPSIT = University of Pennsylvania Smell Identification Test.
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**Summary**: **Aggregate evidence**: D (Level 3: 1 study, Level 4: 1 study)**Benefit**: Improved TDI and UPSIT scores**Harm**: Minimal harm or treatment‐related risk**Cost**: Minimal to moderate, depending on cost of therapy.**Benefit‐Harm assessment**: Balance of benefit and harm**Value judgments**: Limited low‐level evidence is beneficial, but challenging to make a firm recommendation given few studies and low level of evidence. Much like surgical interventions, blinding proves challenging in treatment with TCA.**Recommendation level**: No recommendation

Discussion {#alr22624-sec-0210}
==========

This evidence‐based review with recommendations spans 7 decades of research on PVOD and includes 36 investigations on diverse medical and non‐traditional therapies. In this review, olfactory training has emerged as the most efficacious treatment option for PVOD, supported by the highest level of evidence, a low risk profile, and is a recommendation for the treatment of PVOD. Our review revealed a common theme that a shorter duration of OD prior to OT was found to be associated with improved olfactory outcomes, such that earlier intervention with OT yields better outcomes.[^48^](#alr22624-bib-0048){ref-type="ref"}, [^49^](#alr22624-bib-0049){ref-type="ref"}, [^50^](#alr22624-bib-0050){ref-type="ref"}, [^51^](#alr22624-bib-0051){ref-type="ref"}, [^52^](#alr22624-bib-0052){ref-type="ref"}, [^54^](#alr22624-bib-0054){ref-type="ref"} Though not identified in the included studies, treatment compliance with OT is challenging in some reports.[^58^](#alr22624-bib-0058){ref-type="ref"}

Moreover, systemic or topical steroids are among the most widely acknowledged treatment options for OD, thought to be effective in PVOD by reducing subclinical inflammation.[^4^](#alr22624-bib-0004){ref-type="ref"}, [^59^](#alr22624-bib-0059){ref-type="ref"}, [^60^](#alr22624-bib-0060){ref-type="ref"} However, given the weak evidence available, the potential for olfactory improvement after systemic steroid therapy must be considered against the tangible risks and side effects related to these medications. Despite an encouraging safety profile of topical steroid application, the heterogeneous data presented here makes conclusions regarding their use challenging. One exception may be the addition of topical budesonide therapy to OT, which showed good efficacy in the RCT by Nguyen and Patel.[^54^](#alr22624-bib-0054){ref-type="ref"} Overall, this suggests that use of short‐term systemic and/or topical steroids is an appropriate option in a select subset of patients without underlying risk factors, after a thorough discussion on the potential risks of steroids has taken place with the provider.

Studies of nonsteroidal oral and topical medications are heterogeneous in nature. Though there is reassuring pilot data for oral medications like alpha‐lipoic acid,[^45^](#alr22624-bib-0045){ref-type="ref"} phosphodiesterase inhibitors,[^38^](#alr22624-bib-0038){ref-type="ref"}, [^39^](#alr22624-bib-0039){ref-type="ref"} and caroverine,[^42^](#alr22624-bib-0042){ref-type="ref"} these studies are limited in both size and study design. The data for intranasal sodium citrate spray shows great promise from initial studies, but more definitive data is needed with clinically relevant long‐term outcomes. There is not enough evidence at this time to warrant a recommendation of these treatments for clinical use. Based on current evidence, antibiotic treatment, zinc sulfate, vitamin A, and Gingko biloba failed to demonstrate clinical efficacy in controlled studies and do not appear to play a role in the management of PVOD.

At the time of this writing, in the face of the COVID‐19 pandemic, we now know that a significant proportion of patients infected with SARS‐CoV‐2 have at least a temporary olfactory loss.[^8^](#alr22624-bib-0008){ref-type="ref"}, [^9^](#alr22624-bib-0009){ref-type="ref"}, [^10^](#alr22624-bib-0010){ref-type="ref"} It is plausible that if even a small fraction of patients experience lasting OD, this could represent an enormous total number.[^53^](#alr22624-bib-0053){ref-type="ref"} Given the relatively recent appreciation of this form of viral‐associated OD, definitive outcomes of COVID‐associated PVOD are not yet fully understood. It is nonetheless notable though, that evidence from investigations of prior coronavirus outbreaks (SARS‐CoV‐1 and Middle East respiratory syndrome (MERS)), suggests that systemic corticosteroid treatment may impair viral clearance from the body.[^61^](#alr22624-bib-0061){ref-type="ref"} As such, based on our current understanding of the available evidence, there may be additional risk associated with systemic steroid therapy for the treatment of COVID‐19‐associated PVOD in the acute setting, and it should likely be avoided. We believe in light of the efficacy of OT and relative paucity of other effective pharmacotherapies for non‐COVID PVOD, this knowledge should serve as an impetus to increase the prompt implementation of OT in patients experiencing PVOD following infection with SARS‐CoV‐2.

Conclusion {#alr22624-sec-0220}
==========

This review evaluated all reported treatment options for the management of PVOD and their associated outcomes, based on a specific protocol for evidence‐based review and recommendations. An evidence‐based treatment algorithm of patients with PVOD includes a recommendation of the use of OT, ideally with early utilization following the onset of the PVOD. Furthermore, in the appropriate setting, healthcare providers may offer a course of systemic or topical steroids, after acknowledging the risks associated with systemic steroids and the potential lack of added benefit.

Potential future research options should directly investigate patients with POVD, distinct from other etiologies, and include: Evaluation of optimal timing of initiation of olfactory training.Evaluation of strategies to improve OT compliance and accessibility in regions where OT is less commonly utilized (eg, United States)Further evaluation of adjunctive therapies (eg, oral or topical steroids) to olfactory training that may augment treatment outcomes.More rigorous evaluation and longer‐term outcomes of promising therapeutic strategies such as alpha‐lipoic acid and topical therapies (eg, sodium citrate).Evaluation of impact of timing of initial therapies on treatment outcomes.
